Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease.

ABSTRACT: The rapid spread of COVID-19 has caused a worldwide public health crisis. For prompt and effective development of antivirals for SARS-CoV-2, the pathogen of COVID-19, drug repurposing has been broadly conducted by targeting the main protease (M^Pro), a key enzyme responsible for the replication of virus inside the host. In this study, we evaluate the inhibition potency of a nitrothiazole-containing drug, halicin, and reveal its reaction and interaction mechanism with M^Pro. The in vitro potency test shows that halicin inhibits the activity of M^Pro an IC₅₀ of 181.7 ​nM. Native mass spectrometry and X-ray crystallography studies clearly indicate that the nitrothiazole fragment of halicin covalently binds to the catalytic cysteine C145 of M

SUBMITTER: Yang KS 

PROVIDER: S-EPMC9023366 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature